#39127 Mouse Interferon-γ (mIFN-γ)
|Recombinant mouse IFN-γ was expressed in E. coli and is supplied in a lyophilized form. A greater than 95% purity was determined by SDS-PAGE. Endotoxin levels are less than or equal to 1 EU / 1 μg mIFN-γ.|
|The bioactivity of mIFN-γ was determined in a virus protection assay. The biological activity of each lot is greater than or equal to 1.0 x 10^7 units/mg.|
The purity of recombinant mIFN-γ was determined by SDS-PAGE of 1 µg reduced (+) and non-reduced (-) recombinant mIFN-γ and staining overnight with Coomassie Blue.
The bioactivity of recombinant mIFN-γ was determined in a virus protection assay. L-929 cells were pretreated with increasing concentrations of mIFN-γ (started at 25 pg/ml). Cells were then inoculated with encephalomyocarditis virus (EMCV). The OD590 was determined for the surviving cells.
IFN-γ plays key roles in both the innate and adaptive immune response. IFN-γ activates the cytotoxic activity of innate immune cells such as macrophages and NK cells (1,2). IFN-γ production by NK cells and antigen-presenting cells (APCs) promotes cell-mediated adaptive immunity by inducing IFN-γ production by T lymphocytes, increased class I and class II MHC expression, and enhancing peptide antigen presentation (1). The anti-viral activity of IFN-γ is due to its induction of PKR and other regulatory proteins. Binding of IFN-γ to the IFNGR1/IFNGR2 complex promotes dimerization of the receptor complexes. Binding induces a conformational change in receptor intracellular domains and signaling involves Jak1, Jak2, and Stat1 (3). The critical role of IFN-γ in amplification of immune surveillance and function is supported by increased susceptibility to pathogen infection by IFN-γ or IFNGR knockout mice, and in humans with inactivating mutations in IFNGR1 or IFNGR2. IFN-γ also appears to have a role in atherosclerosis (4).
|9172 Stat1 Antibody|
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.